Unprecedented Overall Survival in 1L Unresectable or mHCC

42% reduced risk of death demonstrated with TECENTRIQ + Avastin® (bevacizumab) vs sorafenib 1


  • OS was a coprimary endpoint

Additional OS analysis 1

  • Exploratory analyses showed that the subset of patients (20%) who were ADA positive by Week 6 appeared to have reduced efficacy as compared to patients (80%) who tested negative for treatment-emergent ADA by Week 6. ADA-positive patients by Week 6 appeared to have similar OS compared to sorafenib-treated patients. However, the analyses were inconclusive due to the low number of events in ADA subgroups

1L=first line; ADA=antidrug antibody; CI=confidence interval; HR=hazard ratio; mHCC=metastatic hepatocellular carcinoma; NE=not estimable; OS=overall survival.

Select Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis and renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

Please see below and the TECENTRIQ Prescribing Information for additional Important Safety Information.

Significantly Improved Progression-free Survival

TECENTRIQ + Avastin demonstrated a 41% reduction in disease progression or death vs sorafenib 1


  • PFS as assessed by IRF per RECIST v1.1 was a coprimary endpoint

HSCT=hematopoietic stem cell transplantation; IRF=independent review facility; PFS=progression-free survival; RECIST=Response Evaluation Criteria In Solid Tumors.